Magnetic resonance spectroscopy
This article was originally published in The Gray Sheet
American College of Radiology requests that CMS issue a national coverage decision for MRS to measure specific metabolites within a pre-determined volume of brain tissue for diagnosing lesions. The agency is accepting comments through Oct. 5 and is scheduled to make a decision by Dec. 5...
You may also be interested in...
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.